Published in Hepatology on October 01, 2001
Viral hepatitis in HIV infection. N Engl J Med (2007) 4.18
KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol (2012) 2.10
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int (2015) 1.92
Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol (2002) 1.81
Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol (2007) 1.78
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology (2007) 1.72
Antiviral resistance and hepatitis B therapy. Hepatology (2009) 1.67
Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int (2011) 1.21
Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol (2009) 1.18
Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int (2007) 1.13
Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat (2012) 1.09
KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol (2016) 1.07
Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J Clin Microbiol (2007) 1.07
Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains. Antimicrob Agents Chemother (2014) 1.04
52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. PLoS One (2013) 1.01
Characterization of a new sensitive PCR assay for quantification of viral DNA isolated from patients with hepatitis B virus infections. J Clin Microbiol (2007) 0.99
Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. Curr Hepat Rep (2011) 0.99
The Roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B. Hepatol Int (2008) 0.98
Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. Gut Liver (2011) 0.97
Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir. Antimicrob Agents Chemother (2012) 0.97
Then and now: the progress in hepatitis B treatment over the past 20 years. World J Gastroenterol (2014) 0.95
A comparison of 48-week treatment efficacy between clevudine and entecavir in treatment-naïve patients with chronic hepatitis B. Hepatol Int (2011) 0.95
Future prospectives for the management of chronic hepatitis B. World J Gastroenterol (2007) 0.91
Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant. Comp Hepatol (2006) 0.91
Monitoring during and after antiviral therapy for hepatitis B. Hepatology (2009) 0.91
Management of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelines. Gut Liver (2010) 0.90
HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya. J Viral Hepat (2011) 0.89
Long-term follow-up study of Chinese patients with YMDD mutations: significance of hepatitis B virus genotypes and characteristics of biochemical flares. J Clin Microbiol (2004) 0.88
Continuous long-term entecavir therapy in naïve chronic hepatitis B patients showing partial virologic response. Gut Liver (2013) 0.88
Molecular biology of hepatitis B virus: effect of nucleotide substitutions on the clinical features of chronic hepatitis B. Med Mol Morphol (2006) 0.87
Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B. Drug Des Devel Ther (2013) 0.87
Clinical evaluation of the digene hybrid capture II test and the COBAS AMPLICOR monitor test for determination of hepatitis B virus DNA levels. J Clin Microbiol (2004) 0.87
Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay. J Clin Microbiol (2007) 0.87
Management of antiviral drug resistance in chronic hepatitis B. World J Gastroenterol (2014) 0.85
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B. Antimicrob Agents Chemother (2009) 0.83
Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: a head-to-head study. Saudi J Gastroenterol (2014) 0.83
Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir. Clin Mol Hepatol (2017) 0.82
Detection of mixed populations of wild-type and YMDD hepatitis B variants by pyrosequencing in acutely and chronically infected patients. BMC Microbiol (2012) 0.82
Adding interferon to lamivudine enhances the early virologic response and reversion of the precore mutation in difficult-to-treat HBV infection. J Gastroenterol (2008) 0.81
Time for an active antiviral therapy for hepatitis B: An update on the management of hepatitis B virus infection. Ther Clin Risk Manag (2007) 0.81
A low viral load predicts a higher initial virologic response to adefovir in patients with Lamivudine-resistant chronic hepatitis B. Gut Liver (2010) 0.81
Early detection and quantification of lamivudine-resistant hepatitis B virus mutants by fluorescent biprobe hybridization assay in lamivudine-treated patients. J Gastroenterol (2006) 0.81
Evaluation of the COBAS amplicor HBV monitor assay and comparison with the ultrasensitive HBV hybrid capture 2 assay for quantification of hepatitis B virus DNA. J Clin Microbiol (2005) 0.81
On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48. Hepatol Int (2009) 0.80
Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virus-infected patients undergoing cytotoxic chemotherapy for malignancy. Antimicrob Agents Chemother (2012) 0.80
Response-guided treatment of cirrhotic chronic hepatitis B patients: multicenter prospective study. World J Gastroenterol (2015) 0.80
Lamivudine resistance in children with chronic hepatitis B. World J Hepatol (2015) 0.80
Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B. World J Gastroenterol (2012) 0.79
Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine. BMC Infect Dis (2004) 0.79
Virologic response and breakthrough in chronic hepatitis B Egyptian patients receiving lamivudine therapy. Ann Gastroenterol (2014) 0.79
What physicians should know about the management of chronic hepatitis B in children: East side story. World J Gastroenterol (2014) 0.79
Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients. Clin Mol Hepatol (2015) 0.79
Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics. World J Gastroenterol (2005) 0.79
Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir. Clin Mol Hepatol (2015) 0.78
Optimization therapy for the treatment of chronic hepatitis B. World J Gastroenterol (2014) 0.78
Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B. Korean J Hepatol (2011) 0.78
The level of HBV DNA at month 12 is an important predictor of virological breakthrough during adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance. Dig Dis Sci (2011) 0.78
Antiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferon. World J Hepatol (2015) 0.77
Baseline prognostic factors and statistic model to predict early virological response in telbivudine-treated patients with chronic hepatitis B. Hepat Mon (2013) 0.77
Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at week 24. BMC Gastroenterol (2012) 0.77
Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated With Long-Term Entecavir Treatment Determined With Ultradeep Pyrosequencing: A Retrospective Observational Study. Medicine (Baltimore) (2016) 0.77
Virologic response at 12 months of treatment predicts sustained antiviral efficacy in patients with adefovir-treated Lamivudine-resistant chronic hepatitis B. Gut Liver (2010) 0.77
Application of coamplification at lower denaturation temperature-PCR sequencing for early detection of antiviral drug resistance mutations of hepatitis B virus. J Clin Microbiol (2014) 0.77
New approaches in the management of chronic hepatitis B: role of tenofovir. Infect Drug Resist (2009) 0.76
Rapid re-emergence of YMDD mutation of hepatitis B virus with hepatic decompensation after lamivudine retreatment. World J Gastroenterol (2008) 0.76
HBV and HCV therapy. Viruses (2009) 0.76
Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations. BMC Infect Dis (2011) 0.76
Early entecavir treatment for chronic hepatitis B with severe acute exacerbation. Antimicrob Agents Chemother (2014) 0.76
Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA. Yonsei Med J (2017) 0.75
Viral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis B. World J Gastroenterol (2007) 0.75
Construction and expression of eukaryotic plasmids containing lamivudine-resistant or wild-type strains of Hepatitis B Virus genotype C. World J Gastroenterol (2008) 0.75
On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B. PLoS One (2017) 0.75
Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B. Exp Ther Med (2016) 0.75
Delayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue Therapy. Int J Med Sci (2015) 0.75
Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B. Clin Mol Hepatol (2016) 0.75
Efficacy of Real-world Entecavir Therapy in Treatment-naïve Chronic Hepatitis B Patients. Chin Med J (Engl) (2017) 0.75
Clinical Course of Partial Virologic Response with Prolonged Tenofovir Therapy in Nuclos(t)ides-Naïve Patients with Chronic Hepatitis B. Dig Dis Sci (2017) 0.75
Clinical course of patients with chronic hepatitis B with viral breakthrough during long-term lamivudine treatment. J Gastroenterol (2005) 0.75
Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology (1987) 3.65
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology (2000) 3.58
Rapid mapping of transposon insertion and deletion mutations in the large Ti-plasmids of Agrobacterium tumefaciens. Nucleic Acids Res (1979) 3.55
Foreign body aspiration into the lower airway in Chinese adults. Chest (1997) 3.54
The functional organization of the octopine Agrobacterium tumefaciens plasmid pTiB6s3. Plasmid (1981) 2.84
Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology (2001) 2.72
Adult-to-adult living donor liver transplantation using extended right lobe grafts. Ann Surg (1997) 2.44
Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol (2007) 2.35
Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology (2000) 2.26
alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology (1989) 2.20
Treatment of duodenal ulcer with antacid and sulpiride. A double-blind controlled study. Gastroenterology (1979) 1.81
Clear cell carcinoma of liver. An ultrastructural study. Cancer (1983) 1.72
Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. J Hepatol (1990) 1.59
Mapping the lectin-like activity of tumor necrosis factor. Science (1994) 1.52
Does treatment of Helicobacter pylori with antibiotics alone heal duodenal ulcer? A randomised double blind placebo controlled study. Gut (1997) 1.47
Necrotizing enterocolitis in neonates with symptomatic congenital heart disease. J Pediatr (1988) 1.46
A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology (1992) 1.44
Hepatocarcinogenesis. Trop Gastroenterol (1990) 1.44
Histologic prognostic indicators in hepatocellular carcinoma. Cancer (1979) 1.43
Synergism of chronic alcoholism and hepatitis B infection in liver disease. J Gastroenterol Hepatol (1991) 1.40
A patient with large granular lymphocytosis of unusual phenotype and polymorphic T-cell receptor beta-chain gene rearrangement. Am J Clin Pathol (1990) 1.40
Validation of the INNO-LIA syphilis kit as a confirmatory assay for Treponema pallidum antibodies. J Clin Microbiol (2000) 1.39
Cholestatic jaundice caused by sequential carbimazole and propylthiouracil treatment for thyrotoxicosis. Hong Kong Med J (2003) 1.38
Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am J Pathol (1996) 1.35
Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. N Engl J Med (1981) 1.34
Sucralfate overcomes adverse effect of cigarette smoking on duodenal ulcer healing and prolongs subsequent remission. Gastroenterology (1987) 1.33
Genetic organization and heterogeneity of the iceA locus of Helicobacter pylori. Gene (2000) 1.33
Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology (2001) 1.32
Nucleic acid-based cross-linking assay for detection and quantification of hepatitis B virus DNA. J Clin Microbiol (1999) 1.29
Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: implications in hepatitis B vaccination programs. Hepatology (1988) 1.28
Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology (2000) 1.27
Poor performance of hepatitis C antibody tests in hospital patients in Uganda. J Med Virol (2010) 1.25
Mannose binding lectin gene mutations are associated with progression of liver disease in chronic hepatitis B infection. Hepatology (1999) 1.25
Hepatitis B virus infection in Chinese families in Hong Kong. Am J Epidemiol (1987) 1.24
Treatment of chronic hepatitis B. Lancet Infect Dis (2001) 1.22
Effect of omeprazole on duodenal ulcer-associated antral gastritis and Helicobacter pylori. Dig Dis Sci (1991) 1.20
Clinical features of hepatocellular carcinoma: review of 211 patients in Hong Kong. Cancer (1981) 1.19
Persistence of Campylobacter pyloridis despite healing of duodenal ulcer and improvement of accompanying duodenitis and gastritis. Dig Dis Sci (1987) 1.18
Expression of c-Myc, c-Fos, and c-jun in hepatocellular carcinoma. Cancer (2001) 1.16
Health-related quality of life of Southern Chinese with chronic hepatitis B infection. Health Qual Life Outcomes (2009) 1.16
Natural history of chronic hepatitis B virus infection. J Gastroenterol Hepatol (2000) 1.15
Long-term prospective follow-up of endoscopic oesophagitis in southern Chinese--prevalence and spectrum of the disease. Aliment Pharmacol Ther (2002) 1.14
Ageing in China: health and social consequences and responses. Int J Epidemiol (2002) 1.14
Hepatitis B infection in patients with lymphomas. Hematol Oncol (1991) 1.12
Current seroepidemiology of hepatitis A in Hong Kong. J Med Virol (1991) 1.12
Effect of cimetidine on gonadal function in man. Br J Clin Pharmacol (1982) 1.11
Soluble E-cadherin is a valid prognostic marker in gastric carcinoma. Gut (2001) 1.11
Incidence and subtypes of dementia in southern Taiwan: impact of socio-demographic factors. Neurology (1998) 1.09
Prevalence and subtypes of dementia in southern Taiwan: impact of age, sex, education, and urbanization. J Neurol Sci (1998) 1.09
Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med (1989) 1.09
The role of hepatic arterial embolization in the treatment of spontaneous rupture of hepatocellular carcinoma. Clin Radiol (1998) 1.08
Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet (1988) 1.08
Minimum graft volume for successful adult-to-adult living donor liver transplantation for fulminant hepatic failure. Transplantation (1996) 1.07
Inhibition of sulpiride on the cephalic phase of gastric acid and gastrin secretion in duodenal ulcer patients. Scand J Gastroenterol (1976) 1.07
Acute cholangitis--predictive factors for emergency ERCP. Aliment Pharmacol Ther (2001) 1.05
Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Hepatology (1997) 1.05
Sequential intravenous/oral antibiotic vs. continuous intravenous antibiotic in the treatment of pyogenic liver abscess. Aliment Pharmacol Ther (2002) 1.04
A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology (1988) 1.04
Trends in the prevalence of peptic ulcer disease and Helicobacter pylori infection in family physician-referred uninvestigated dyspeptic patients in Hong Kong. Aliment Pharmacol Ther (2005) 1.04
Isolation, purification, and amino acid sequence of lactobin A, one of the two bacteriocins produced by Lactobacillus amylovorus LMG P-13139. Appl Environ Microbiol (1997) 1.03
Validity of the rapid strip assay test for detecting HBsAg in patients admitted to hospital in Uganda. J Med Virol (2010) 1.03
A novel DFNA5 mutation, IVS8+4 A>G, in the splice donor site of intron 8 causes late-onset non-syndromic hearing loss in a Chinese family. Clin Genet (2007) 1.03
Treatment of inoperable hepatocellular carcinoma by transcatheter arterial chemoembolization using an emulsion of cisplatin in iodized oil and gelfoam. Clin Radiol (1993) 1.01
Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment. Antimicrob Agents Chemother (2010) 0.99
Hepatitis virus and HIV infections in inmates of a state correctional facility in Mexico. Epidemiol Infect (2005) 0.99
Efficient secretion of biologically active mouse tumor necrosis factor alpha by Streptomyces lividans. Gene (1994) 0.97
Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy. J Viral Hepat (2007) 0.97
Applicability of living donor liver transplantation to high-urgency patients. Transplantation (1999) 0.97
Factors influencing healing of duodenal ulcer. Control of nocturnal secretion by H2 blockade and characteristics of patients who failed to heal. Dig Dis Sci (1985) 0.97
Precore sequence variation in Chinese isolates of hepatitis B virus. J Infect Dis (1992) 0.96
Seroepidemiological survey of hepatitis E in Hong Kong by recombinant-based enzyme immunoassays. Lancet (1992) 0.96
The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B. J Viral Hepat (2005) 0.96
Assessment of a new immunoassay for serological confirmation and discrimination of human T-cell lymphotropic virus infections. Clin Diagn Lab Immunol (1998) 0.95
Hepatocellular carcinoma expressing both hepatocellular and biliary markers also expresses cytokeratin 14, a marker of bipotential progenitor cells. J Hepatol (1999) 0.95
Human stomach alcohol and aldehyde dehydrogenases: comparison of expression pattern and activities in alimentary tract. Gastroenterology (1997) 0.94
Evaluation of a novel subtilisin inhibitor gene and mutant derivatives for the expression and secretion of mouse tumor necrosis factor alpha by Streptomyces lividans. Appl Environ Microbiol (1997) 0.93
Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong. Gut (1996) 0.93
Interferon therapy of chronic hepatitis B virus infection in Chinese. J Hepatol (1986) 0.92
Novel mutations in the vWFA2 domain of COCH in two Chinese DFNA9 families. Clin Genet (2008) 0.92
Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children. Hepatology (1999) 0.92
Factors determining the development of hepatocellular carcinoma in hepatitis B surface antigen carriers. A comparison between families with clusters and solitary cases. Cancer (1988) 0.91
Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy. J Med Virol (2004) 0.90
Hepatocellular carcinoma in Chinese males and females. Possible causes for the male predominance. Cancer (1987) 0.89
Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg (2001) 0.89
Five-year experience with the development of a liver transplant program in Hong Kong. Transplant Proc (1998) 0.89
Evidence for intrafamilial transmission of hepatitis B virus from sequence analysis of mutant HBV DNAs in two Chinese families. Lancet (1990) 0.89
Transesophageal echocardiography in the detection of inferior vena cava and cardiac metastasis in hepatocellular carcinoma. Clin Cardiol (1996) 0.89
Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther (2001) 0.89
Wilson's disease: 35 years' experience. Q J Med (1990) 0.88
An oligonucleotide probe for the detection of hepatitis B virus DNA in serum. J Virol Methods (1987) 0.88
Morbidity and mortality from chronic hepatitis B virus infection in family members of patients with malignant and nonmalignant hepatitis B virus-related chronic liver diseases. Hepatology (1991) 0.88
Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study. J Viral Hepat (2011) 0.87
Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology (1998) 0.87
Treatment of chronic hepatitis B with interferon: experience in Asian patients. Semin Liver Dis (1989) 0.87
Prevalence and characteristics of familial hepatocellular carcinoma caused by chronic hepatitis B infection in Hong Kong. Aliment Pharmacol Ther (2004) 0.86
Relationship between intrahepatic expression of hepatitis B viral antigens and histology in Chinese patients with chronic hepatitis B virus infection. Am J Clin Pathol (1993) 0.86
Impact of precore and core promoter mutations on hepatic histology in patients with chronic hepatitis B. Aliment Pharmacol Ther (2005) 0.86
Hepatitis B virus genotypes and precore mutations in Scottish blood donors. Vox Sang (2005) 0.86